Efficacy of the Protease Inhibitors Tipranavir plus Ritonavir in Treatment-Experienced Patients: 24-Week Analysis from the RESIST-1 Trial

This publication has 31 references indexed in Scilit:

• Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial
  Clinical Infectious Diseases, 2006
• Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers
  HIV Research & Clinical Practice, 2004
• Peptidomimetic Inhibitors of HIV Protease
  Current Topics in Medicinal Chemistry, 2004
• Tipranavir: a novel non-peptidic protease inhibitor for the treatment of HIV infection
  Expert Opinion on Investigational Drugs, 2003
• Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers
  British Journal of Clinical Pharmacology, 2001
• Drug Resistance and Predicted Virologic Responses to Human Immunodeficiency Virus Type 1 Protease Inhibitor Therapy
  The Journal of Infectious Diseases, 2000
• Determinants of Virological Response to Antiretroviral Therapy: Implications for Long-Term Strategies
  Clinical Infectious Diseases, 2000
• Outcome and Predictors of Failure of Highly Active Antiretroviral Therapy: One‐Year Follow‐Up of a Cohort of Human Immunodeficiency Virus Type 1–Infected Persons
  The Journal of Infectious Diseases, 1999
• Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study
  The Lancet, 1999
• Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus Infection
  New England Journal of Medicine, 1998